Can a vitamin a drug boost platelets in Hard-to-Treat ITP?

NCT ID NCT07597395

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests all-trans retinoic acid (ATRA), a form of vitamin A, in adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite steroid treatment. About 192 participants will receive either ATRA or a placebo for 24 weeks. The goal is to see if ATRA can safely raise platelet counts to safer levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: all-trans retinoic acid (ATRA), also known as tretinoin
What this could lead to: If it works, this could provide a new treatment option for adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite standard steroid therapy.
What could go wrong: This is a phase 3 trial, but it hasn't started recruiting yet. ATRA may not improve platelet counts more than placebo, and side effects like skin dryness or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

Peking University Institute of hematology, People's Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.